APPLICATION
ANDA090776
TYPE
ANDA
ORIGINAL APPROVAL
2013-12-17
LATEST ACTION
2024-05-31
ROUTE
ORAL
DOSAGE FORM
CAPSULE, DELAYED REL PELLETS
MARKETING STATUS
Prescription
Products
DULOXETINE HYDROCHLORIDEPrescription
DULOXETINE HYDROCHLORIDE EQ 30MG BASE · CAPSULE, DELAYED REL PELLETS · ORAL
DULOXETINE HYDROCHLORIDEPrescription
DULOXETINE HYDROCHLORIDE EQ 60MG BASE · CAPSULE, DELAYED REL PELLETS · ORAL
DULOXETINE HYDROCHLORIDEPrescription
DULOXETINE HYDROCHLORIDE EQ 20MG BASE · CAPSULE, DELAYED REL PELLETS · ORAL
Approval history
2024-05-31Labeling · Supplement 22 · standardAP
2023-05-02Labeling · Supplement 17 · standardAP
2023-05-02Labeling · Supplement 11 · standardAP
2023-05-02Labeling · Supplement 18 · standardAP
2023-05-02Labeling · Supplement 14 · standardAP
2023-05-02Labeling · Supplement 8 · standardAP
2023-05-02Labeling · Supplement 10 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.